Advertisement



More in Pharmacy

Shelling out nearly $16,000 for a 14-day course of medication is what to expect for the wholesale cost of Zurzuvae, the first oral treatment for postpartum depression, according to a Nov. 7 news release from drugmaker Sage Therapeutics. 

After a three-day walkout of retail pharmacy employees across the U.S., organizers of the grassroots labor action created an organization that seeks to unionize the workforce and advocate for safer working conditions. 

As 2023 entered its fourth quarter, one cancer drug shortage resolved as more than a dozen continue; a California system helped make a chemotherapy management app; and the FDA approved a new head and neck cancer medication. 

On Nov. 8, the FDA approved Eli Lilly's Zepbound (tirzepatide), a weekly injection for chronic weight management. 

Accord Healthcare, a London-based drugmaker, resumed manufacturing of two methotrexate solutions, according to a Nov. 7 update from the FDA. 

The FDA is investigating reports of hospitalizations tied to suspected counterfeit versions of semaglutide drugs, including three in the U.S., according to records from the agency's adverse event reporting system. 

As hundreds of pharmacy and imaging workers for Kaiser Permanente strike, a spokesperson for the system told CBS affiliate KPIC their union's ask for a 43% raise over the next four years is "frankly, not reasonable."

Pneumonia patients who took an antibiotic that's typically reserved as an alternative were less likely to develop Clostridioides difficile infections compared to those taking the recommended drug, according to a study from Veterans Affairs Hospitals. 

Organizations representing thousands of hospital pharmacies are criticizing CMS' plan to not provide further reimbursement to 340B hospitals after paying a $9 billion lump sum. 

Advertisement
Advertisement
Advertisement